ClinicalTrials.gg
RecruitingNCT05834803DAN-PTRAIIUpdated Nov 13, 2026

Effects of Percutaneous Transluminal Renal Angioplasty of Atherosclerotic Renal Artery Stenosis in High-Risk Patients.

An interventional study of Optimal medical therapy (OMT) and Catheter-based angiography in Renovascular Hypertension, Renovascular Hypertension With Renal Failure and Heart Failure, sponsored by University of Aarhus. Recruiting at 3 sites in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by University of Aarhus · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2023; still recruiting 3 years 4 months later.
Updated Nov 13, 2026Study documents postedEligibility revised+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies in Heart Failure by University of Aarhus — 4 open to participants now, 4 under way, none of them phase 3. Heart Failure · University of Aarhus.

Planned enrollment
6th of 22
80 · median 23
Started
2023
the only one that year
No phase
10 of 29
2 open now
Registered
26th of 29
by date

Among the 29 studies in Heart Failure by University of Aarhus, this one is the 6th largest by planned enrollment of the 22 interventional ones that give a count, is the only one that started in 2023, is one of 10 with no phase, and was the 26th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

4 of the 29 studies in Heart Failure by University of Aarhus are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Heart Failure by University of Aarhus, or all of them as a file.
02

Study summary

The goal of this clinical trial is to investigate whether percutaneous transluminal renal angioplasty (PTRA) with stent placement of atherosclerotic renal artery stenosis is beneficial in high-risk patients selected according to the criteria used in the DAN-PTRAI study. The main questions the trial aims to answer are whether renal artery stenting in addition to optimal medical therapy, compared with a sham procedure and optimal medical therapy, has beneficial effects on:

  • Blood pressure (primary outcome: 24-hour ambulatory systolic blood pressure at 6 months)
  • Kidney function
  • Hospitalizations for heart failure
Read the detailed description

Even with optimal medical care, patients with renovascular disease have a very high risk of cardiovascular events and an expected poor outcome. One treatment option of atherosclerotic renal artery stenosis is percutaneous transluminal renal angioplasty with stent placement. Renal artery stenting is, however, still a subject of debate as randomized trials have failed to show a benefit of this compared with optimal medical treatment alone. Following the results of the large CORAL trial in 2014, we established the national prospective DAN-PTRAI study using strict and well-defined criteria to select patients for renal artery stenting. In this study, we observed a reduction in blood pressure, an improved kidney function, and a decrease in new hospital admissions due to heart failure after renal artery stenting.

The DAN-PTRAII study is a nationwide randomized, sham-controlled clinical trial in patients with severe renovascular disease due to atherosclerotic renal artery stenosis. Only patients who fulfill the inclusion criteria on optimal medical treatment can enter the study and only the operator and the interventional team will know whether the patients receive renal artery stenting or sham treatment. Participants will be followed closely for 6 months after the treatment to evaluate the effects of renal artery stenting compared with a sham procedure, both in addition to optimal medical therapy, on blood pressure, kidney function, and hospitalizations for heart failure.

03

Conditions studied

  • Renovascular Hypertension
  • Renovascular Hypertension With Renal Failure
  • Heart Failure
  • Renal Artery Stenosis Atherosclerotic

Keywords

  • percutaneous transluminal angioplasty
  • renal artery stenosis
  • renal artery stenting
  • sham-controlled
  • renovascular disease
04

Who can participate

The criteria were revised on the registry on Nov 4, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. One or more severe atherosclerotic renal artery stenoses defined as a stenosis ≥70% by catheter-based angiography.
  2. In addition, at least one of the following high-risk clinical syndromes:

    1. Resistant hypertension with average 24-hour ambulatory systolic blood pressure ≥150 mmHg despite ≥3 antihypertensive drugs including a diuretic, if tolerated, and each prescribed at optimal doses.
    2. Rapidly declining kidney function with a reduction in estimated of >5 mL/min per 1.73m2 per year and average 24-hour ambulatory systolic blood pressure ≥140 mmHg despite ≥3 antihypertensive drugs including a diuretic, if tolerated, and each prescribed at optimal doses.
    3. Hospital admissions with acute decompensated heart failure (≥2 hospitalizations for heart failure or ≥1 hospitalization for sudden, "flash" pulmonary edema) with no obvious explanations such as nonadherence, \<40%, or valvular heart disease and average 24-hour ambulatory systolic blood pressure ≥140 mmHg despite ≥3 antihypertensive drugs including a diuretic, if tolerated, and each prescribed at optimal doses.

All 24-hour ambulatory blood pressure measurements are performed after nurse-administered medication.

Exclusion criteria

Exclusion Criteria:

  • Unable to provide .
  • Treatment-resistant heart failure episodes presumed caused by renovascular disease.
  • Rapidly declining kidney function/acute kidney failure approaching the need for dialysis presumed caused by renovascular disease.
  • Fibromuscular dysplasia or other non-atherosclerotic renal artery stenosis known to be present prior to randomization.
  • Pregnancy or unknown pregnancy status in female of .
  • Kidney size \<7 cm (pole to pole length) supplied by target vessel.
  • Previous kidney transplant.
  • Previous PTRA with stent placement.
  • Presence of a renal artery stenosis not amenable for treatment with a stent.
  • Intolerance to any antithrombotic treatment.

Patients who are not eligible for randomization but treated with renal artery stenting outside the protocol are followed according to the DAN-PTRAII protocol in order to account for all PTRA treatments performed in Denmark in the study period.

Patients treated with renal artery stenting without randomization in the study period include patients with:

  1. Treatment-resistant heart failure episodes presumed caused by renovascular disease.
  2. Rapidly declining kidney function/acute kidney failure approaching the need for dialysis presumed caused by renovascular disease.
  3. At least one of the listed high-risk clinical syndromes AND one or more significant atherosclerotic renal artery stenoses defined as a stenosis of 50-69% by catheter-based angiography with:

    • a mean translesional gradient of ≥10 mmHg, or
    • a systolic translesional gradient of ≥20 mmHg, or
    • a renal fractional flow reserve (Pd/Pa) of ≤0.80
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Renal artery stenting

    Percutaneous transluminal renal angioplasty with stent placement

    Drug: Optimal medical therapy (OMT) · Diagnostic Test: Catheter-based angiography · Diagnostic Test: Measurement of translesional pressure gradients · Procedure: Renal artery stenting

  • Sham comparator
    Sham procedure

    Sham procedure

    Drug: Optimal medical therapy (OMT) · Diagnostic Test: Catheter-based angiography · Diagnostic Test: Measurement of translesional pressure gradients · Procedure: Sham (No Treatment)

Interventions

  • DrugOptimal medical therapy (OMT)

    Optimal medical therapy, including maximally tolerated renin-angiotensin system blockade with either an angiotensin-converting enzyme inhibitor or an angiotensin II receptor blocker.

  • Diagnostic testCatheter-based angiography

    Catheter-based angiography performed in accordance with the study protocol.

  • Diagnostic testMeasurement of translesional pressure gradients

    Measurement of translesional pressure gradients performed in accordance with the study protocol.

  • ProcedureRenal artery stenting

    Renal artery stenting performed in accordance with the study protocol.

  • ProcedureSham (No Treatment)

    Sham procedure performed in accordance with the study protocol.

06

What researchers measure

Primary outcomes

  1. Change in 24-hour ambulatory systolic blood pressure

    Defined as the between-group difference in the change in 24-hour ambulatory systolic blood pressure from baseline to 6 months.

    Time frame: Baseline and 6 months

Secondary outcomes

  1. Change in estimated glomerular filtration rate (eGFR)

    Defined as the between-group difference in the change in estimated glomerular filtration rate (eGFR) from baseline to 6 months.

    Time frame: Baseline, Day 1, Day 7, Day 21, 6 weeks, 3 months, 4.5 months, and 6 months

  2. Change in urine albumin-to-creatinine ratio (UACR)

    Defined as the between-group difference in the change in urine albumin-to-creatinine ratio from baseline to 3 and 6 months.

    Time frame: Baseline, 3 months, and 6 months

  3. Change in attended automated office systolic blood pressure

    Defined as the between-group difference in the change in attended automated office systolic blood pressure from baseline to 3 and 6 months.

    Time frame: Baseline, 3 months, and 6 months

  4. Change in unattended automated office systolic blood pressure

    Defined as the between-group difference in the change in unattended automated office systolic blood pressure from baseline to 3 and 6 months.

    Time frame: Baseline, 3 months, and 6 months

  5. Change in defined daily dose (DDD) of antihypertensive medications

    Defined as the between-group difference in the change in defined daily dose (DDD) of antihypertensive medications from baseline to 3 and 6 months.

    Time frame: Baseline, 3 months, and 6 months

  6. Change in the number of antihypertensive medications

    Defined as the between-group difference in the change in the number of antihypertensive medications from baseline to 3 and 6 months.

    Time frame: Baseline, 3 months, and 6 months

  7. Change in 24-hour ambulatory systolic blood pressure (corrected for changes in antihypertensive medication)

    Defined as the between-group difference in the change in 24-hour ambulatory systolic blood pressure from baseline to 3 and 6 months, corrected for changes in antihypertensive medication burden (1 DDD = 5 mmHg).

    Time frame: Baseline, 3 months, and 6 months

  8. Number of participants with cardiovascular or kidney outcomes

    Between-group comparison of the number of participants with clinical events from baseline to 6 months. Clinical events are defined using the same criteria as in the Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL) trial, except for progressive renal insufficiency (defined in CORAL as a reduction from baseline of 30% or more in estimated GFR). Clinical events included in the composite endpoint from baseline to 6-month follow-up are: 1. Death from cardiovascular causes 2. Death from renal causes 3. Stroke 4. Myocardial infarction 5. Hospitalization for congestive heart failure 6. Progressive renal insufficiency (a reduction from baseline of 50% or more in estimated GFR) 7. Permanent renal-replacement therapy Only the first event per participant is included in the composite.

    Time frame: From baseline to 6 months

  9. Number of deaths from any cause

    Between-group comparison of the number of participants with death from any cause from baseline to 6 months.

    Time frame: From baseline to 6 months

  10. Change in health status on 12-item Short Form Health Survey (SF-12)

    Defined as the between-group difference in the change in 12-item Short Form Health Survey (SF-12) scores from baseline to 3 and 6 months. Scores range from 0 to 100, with higher scores indicating better physical and mental health functioning.

    Time frame: Baseline, 3 months, and 6 months

  11. Number of serious adverse events (SAEs) during follow-up and procedure-related and postoperative adverse events within 30 days after the procedure

    All SAEs occurring from baseline to 6 months, as well as procedure-related adverse events (≤24 hours) and postoperative adverse events (\>24 hours) occurring within 30 days after the procedure, will be systematically recorded and compared between groups as the proportion of participants with at least one event. Events include, but are not limited to: 1. Death from any cause 2. Rupture, dissection, occlusion, or perforation of the renal artery 3. Stent thrombosis of the PTRA-treated renal artery 4. Embolic complications affecting the kidney or peripheral circulation (upper or lower extremity depending on access site) 5. Bleeding requiring transfusion 6. Embolization or nephrectomy due to bleeding or other complications 7. Access-related complications requiring treatment: bleeding, thrombosis, or pseudoaneurysm 8. Need for acute dialysis 9. Clinical events as defined above

    Time frame: From baseline to 6 months (SAEs); from baseline to 30 days (procedure-related and postoperative adverse events)

  12. Change in intrarenal resistive index

    Defined as the between-group difference in the change in intrarenal resistive index (unitless) of the affected kidney from baseline to 6 months, measured by Doppler ultrasound. Additional renal ultrasound and Doppler parameters (kidney length, peak systolic velocity, acceleration time, renal-renal ratio, and pulsatility index) will be assessed at baseline and 6 months and compared between groups. In exploratory analyses, the association between baseline intrarenal resistive index (≥0.80 vs \<0.80) and the change in 24-hour ambulatory systolic blood pressure and eGFR from baseline to 6 months will be evaluated, and the diagnostic accuracy (sensitivity and specificity) of baseline Doppler ultrasound for identifying hemodynamically significant renal artery stenosis will be assessed using invasive pressure measurement as the reference standard.

    Time frame: Baseline and 6 months

  13. Change in left ventricular mass index

    Defined as the between-group difference in the change in left ventricular mass index (g/m²) from baseline to 6 months, assessed by transthoracic echocardiography. Additional transthoracic echocardiographic parameters of cardiac systolic and diastolic function and cardiac chamber dimensions and volumes will be assessed at baseline and 6 months and compared between groups.

    Time frame: Baseline and 6 months

  14. Change in split renal function of the affected kidney

    Defined as the between-group difference in the change in split renal function (%) of the affected kidney from baseline to 6 months, assessed by renography. The change in renogram configuration (renogram grade) of the affected kidney from baseline to 6 months will be compared between groups as the proportion of participants with improvement in renogram grade. In exploratory analyses, the diagnostic accuracy (sensitivity and specificity) of baseline renography for identifying hemodynamically significant renal artery stenosis will be assessed using invasive pressure measurement as the reference standard, and the association between baseline renography with intermediate/high probability of renal artery stenosis and the change in 24-hour ambulatory systolic blood pressure and eGFR from baseline to 6 months will be evaluated.

    Time frame: Baseline and 6 months

  15. Translesional pressure ratio (Pd/Pa) across renal artery stenoses

    Defined as the distal-to-aortic pressure ratio (Pd/Pa, unitless) across the target renal artery stenosis, measured by intra-arterial pressure assessment during the endovascular procedure. Systolic, diastolic, mean, and pulse pressure gradients (mmHg) across the target renal artery stenosis will be measured invasively during the procedure. In exploratory analyses, the association between baseline Pd/Pa and mean and systolic translesional pressure gradients and the change in 24-hour ambulatory systolic blood pressure and eGFR from baseline to 6 months will be evaluated, and whether the effect of PTRA differs according to baseline Pd/Pa will be explored.

    Time frame: Baseline and 6 months

  16. Agreement between CFD-derived and invasively measured translesional pressure ratio (Pd/Pa)

    Defined as the mean difference (Bland-Altman bias, unitless) between Pd/Pa derived non-invasively from CT angiography using computational fluid dynamics (CFD) and Pd/Pa measured invasively during the endovascular procedure. Agreement between CFD-derived and invasively measured mean and systolic translesional pressure gradients will be assessed correspondingly. In exploratory analyses, the association between CFD-derived Pd/Pa and mean and systolic translesional pressure gradients and the change in 24-hour ambulatory systolic blood pressure and eGFR from baseline to 6 months will be evaluated.

    Time frame: Baseline and 6 months

  17. Change in plasma renin

    Defined as the between-group difference in the change in plasma renin concentration (mIU/L) from baseline to 3 and 6 months. In exploratory analyses, the association between baseline plasma renin and the change in 24-hour ambulatory systolic blood pressure and eGFR from baseline to 6 months will be evaluated.

    Time frame: Baseline, 3 months, and 6 months

  18. Change in plasma aldosterone

    Defined as the between-group difference in the change in plasma aldosterone concentration (pmol/L) from baseline to 3 and 6 months. In exploratory analyses, the association between baseline plasma aldosterone and the change in 24-hour ambulatory systolic blood pressure and eGFR from baseline to 6 months will be evaluated.

    Time frame: Baseline, 3 months, and 6 months

  19. Change in N-terminal pro-B-type natriuretic peptide (NT-proBNP)

    Defined as the between-group difference in the change in plasma NT-proBNP concentration (ng/L) from baseline to 3 and 6 months. In exploratory analyses, the association between changes in echocardiographic parameters, including left ventricular mass index, and the change in NT-proBNP from baseline to 6 months will be evaluated to assess whether changes in NT-proBNP reflect changes in cardiac structure and function.

    Time frame: Baseline, 3 months, and 6 months

  20. Proteomic profile in blood and on the angioplasty balloon

    Defined as the proteomic profile in blood and in material retrieved from the angioplasty balloon after dilation during PTRA. In exploratory analyses, the association between the proteomic profile and the change in 24-hour ambulatory systolic blood pressure and eGFR from baseline to 6 months, and the need for reintervention due to restenosis, will be evaluated. Proteomic analyses will be described in a separate analysis plan.

    Time frame: Baseline and 6 months

07

Study locations

3 of 3 sites recruiting
08

References and documents

Publications

  • Reinhard M, Schousboe K, Andersen UB, Buus NH, Rantanen JM, Bech JN, Mafi HM, Langfeldt S, Bharadwaz A, Horlyck A, Jensen MK, Jeppesen J, Olsen MH, Jacobsen IA, Bibby BM, Christensen KL. Renal Artery Stenting in Consecutive High-Risk Patients With Atherosclerotic Renovascular Disease: A Prospective 2-Center Cohort Study. J Am Heart Assoc. 2022 Apr 5;11(7):e024421. doi: 10.1161/JAHA.121.024421. Epub 2022 Mar 24. PubMed 35322677 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2023 (actual). Primary completion is estimated for Jun 2027, 47 months after the start.

Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 47 months is above that.

Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 3, 2023
First posted
Apr 28, 2023
StartActual
Jun 26, 2023
Primary completionEst.
Jun 1, 2027
CompletionEst.
Jun 1, 2027
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
2 inclusion criteria edited; 4 exclusion criteria edited, 1 added
What changed in the criteria
Inclusion criteria
  • EditedHospital admissions with acute decompensated heart failure (≥2 hospitalizations for heart failure or ≥1 hospitalizationshospitalization for sudden, "flash" pulmonary edema) with no obvious explanations such as nonadherence, left ventricular ejection fraction <40%, or valvular heart disease and average 24-hour ambulatory systolic blood pressure ≥140 mmHg despite ≥3 antihypertensive drugs including a diuretic, if tolerated, and each prescribed at optimal doses.
  • EditedAll 24-hour ambulatory blood pressure monitoringsmeasurements are performed after nurse-administered medication.
Exclusion criteria
  • EditedPrevious PTRA treatmentwith stent placement.
  • AddedIntolerance to any antithrombotic treatment.
  • Editeda mean translesional gradient of ≥10 mm HgmmHg, or
  • Editeda systolic translesional gradient of ≥20 mm HgmmHg, or
  • Editeda renal fractional flow reserve (Pd/Pa) of ≤0.880
Nov 4, 2026
Documents
Secondary outcomes
Revised in 2 updates
What changed on Nov 4, 2026
  • EditedChange in 24-hour ambulatory systolic blood pressure (statistically adjustedcorrected for treatment changeschanges in antihypertensive medication)Time frame: Baseline, 3 months, and 6 months
  • EditedNumber of serious adverse events (SAEs), during follow-up and procedure-related adverse events (≤24 hours), and postoperative adverse events (>24 hours) occurring within 30 days after the procedureTime frame: From baseline to 30 days after PTRA/sham → From baseline to 6 months (SAEs); from baseline to 30 days (procedure-related and postoperative adverse events)
  • AddedChange in urine albumin-to-creatinine ratio (UACR)Time frame: Baseline, 3 months, and 6 months
  • AddedChange in intrarenal resistive indexTime frame: Baseline and 6 months
  • AddedChange in left ventricular mass indexTime frame: Baseline and 6 months
  • AddedChange in split renal function of the affected kidneyTime frame: Baseline and 6 months
  • AddedTranslesional pressure ratio (Pd/Pa) across renal artery stenosesTime frame: Baseline and 6 months
  • AddedAgreement between CFD-derived and invasively measured translesional pressure ratio (Pd/Pa)Time frame: Baseline and 6 months
  • AddedChange in plasma reninTime frame: Baseline, 3 months, and 6 months
  • AddedChange in plasma aldosteroneTime frame: Baseline, 3 months, and 6 months
  • AddedChange in N-terminal pro-B-type natriuretic peptide (NT-proBNP)Time frame: Baseline, 3 months, and 6 months
  • AddedProteomic profile in blood and on the angioplasty balloonTime frame: Baseline and 6 months
  • RemovedEvaluation of Diagnostic TechniquesTime frame: From baseline to 6 months after PTRA/sham
  • Time frameNumber of participants with cardiovascular or kidney outcomesFrom baseline to 6 months after PTRA/sham → From baseline to 6 months
  • Time frameNumber of deaths from any causeFrom baseline to 6 months after PTRA/sham → From baseline to 6 months
  • DescriptionChange in attended automated office systolic blood pressure: how it is measured was reworded
  • DescriptionChange in defined daily dose (DDD) of antihypertensive medications: how it is measured was reworded
  • DescriptionChange in health status on 12-item Short Form Health Survey (SF-12): how it is measured was reworded
  • DescriptionChange in the number of antihypertensive medications: how it is measured was reworded
  • DescriptionChange in unattended automated office systolic blood pressure: how it is measured was reworded
  • DescriptionNumber of deaths from any cause: how it is measured was reworded
  • DescriptionNumber of participants with cardiovascular or kidney outcomes: how it is measured was reworded
What changed on Nov 13, 2026
  • DescriptionChange in split renal function of the affected kidney: how it is measured was reworded
  • DescriptionNumber of serious adverse events (SAEs) during follow-up and procedure-related and postoperative adverse events within 30 days after the procedure: how it is measured was reworded
across 2 updates, Nov 4, 2026 – Nov 13, 2026
Contact
Study contact's phone or email changed: m•••@dadlnet.dk→m•••@rm.dk. See the current contact
Nov 4, 2026
Sponsor
Collaborators added: Copenhagen University Hospital, Rigshospitalet·Novo Nordisk Foundation; collaborators removed: Rigshospitalet, Denmark·The Novo Nordic Foundation
Nov 4, 2026
Show all 2 updates
  1. Nov 13, 2026
    Secondary outcomes 2 description edited
    What changed in the outcomes
    • DescriptionChange in split renal function of the affected kidney: how it is measured was reworded
    • DescriptionNumber of serious adverse events (SAEs) during follow-up and procedure-related and postoperative adverse events within 30 days after the procedure: how it is measured was reworded
    + 1 other change: verification date
  2. Nov 4, 2026
    Eligibility 2 inclusion criteria edited; 4 exclusion criteria edited, 1 added
    What changed in the criteria
    Inclusion criteria
    • EditedHospital admissions with acute decompensated heart failure (≥2 hospitalizations for heart failure or ≥1 hospitalizationshospitalization for sudden, "flash" pulmonary edema) with no obvious explanations such as nonadherence, left ventricular ejection fraction <40%, or valvular heart disease and average 24-hour ambulatory systolic blood pressure ≥140 mmHg despite ≥3 antihypertensive drugs including a diuretic, if tolerated, and each prescribed at optimal doses.
    • EditedAll 24-hour ambulatory blood pressure monitoringsmeasurements are performed after nurse-administered medication.
    Exclusion criteria
    • EditedPrevious PTRA treatmentwith stent placement.
    • AddedIntolerance to any antithrombotic treatment.
    • Editeda mean translesional gradient of ≥10 mm HgmmHg, or
    • Editeda systolic translesional gradient of ≥20 mm HgmmHg, or
    • Editeda renal fractional flow reserve (Pd/Pa) of ≤0.880
    Secondary outcomes 2 edited, 2 time frame changed, 10 added, 1 removed, 7 description edited
    What changed in the outcomes
    • EditedChange in 24-hour ambulatory systolic blood pressure (statistically adjustedcorrected for treatment changeschanges in antihypertensive medication)Time frame: Baseline, 3 months, and 6 months
    • EditedNumber of serious adverse events (SAEs), during follow-up and procedure-related adverse events (≤24 hours), and postoperative adverse events (>24 hours) occurring within 30 days after the procedureTime frame: From baseline to 30 days after PTRA/sham → From baseline to 6 months (SAEs); from baseline to 30 days (procedure-related and postoperative adverse events)
    • AddedChange in urine albumin-to-creatinine ratio (UACR)Time frame: Baseline, 3 months, and 6 months
    • AddedChange in intrarenal resistive indexTime frame: Baseline and 6 months
    • AddedChange in left ventricular mass indexTime frame: Baseline and 6 months
    • AddedChange in split renal function of the affected kidneyTime frame: Baseline and 6 months
    • AddedTranslesional pressure ratio (Pd/Pa) across renal artery stenosesTime frame: Baseline and 6 months
    • AddedAgreement between CFD-derived and invasively measured translesional pressure ratio (Pd/Pa)Time frame: Baseline and 6 months
    • AddedChange in plasma reninTime frame: Baseline, 3 months, and 6 months
    • AddedChange in plasma aldosteroneTime frame: Baseline, 3 months, and 6 months
    • AddedChange in N-terminal pro-B-type natriuretic peptide (NT-proBNP)Time frame: Baseline, 3 months, and 6 months
    • AddedProteomic profile in blood and on the angioplasty balloonTime frame: Baseline and 6 months
    • RemovedEvaluation of Diagnostic TechniquesTime frame: From baseline to 6 months after PTRA/sham
    • Time frameNumber of participants with cardiovascular or kidney outcomesFrom baseline to 6 months after PTRA/sham → From baseline to 6 months
    • Time frameNumber of deaths from any causeFrom baseline to 6 months after PTRA/sham → From baseline to 6 months
    • DescriptionChange in attended automated office systolic blood pressure: how it is measured was reworded
    • DescriptionChange in defined daily dose (DDD) of antihypertensive medications: how it is measured was reworded
    • DescriptionChange in health status on 12-item Short Form Health Survey (SF-12): how it is measured was reworded
    • DescriptionChange in the number of antihypertensive medications: how it is measured was reworded
    • DescriptionChange in unattended automated office systolic blood pressure: how it is measured was reworded
    • DescriptionNumber of deaths from any cause: how it is measured was reworded
    • DescriptionNumber of participants with cardiovascular or kidney outcomes: how it is measured was reworded
    Sponsor Collaborators added: Copenhagen University Hospital, Rigshospitalet·Novo Nordisk Foundation; collaborators removed: Rigshospitalet, Denmark·The Novo Nordic Foundation
    Contact Study contact's phone or email changed: m•••@dadlnet.dk→m•••@rm.dk. See the current contact
    + 6 other changes: index terms, verification date, description, conditions, design details and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05834803
Collaborators
Aarhus University Hospital, Copenhagen University Hospital, Rigshospitalet, Odense University Hospital, Aalborg University Hospital, Gødstrup Hospital, Holbaek Sygehus, Amsterdam UMC, The Augustinus Foundation, Denmark., Novo Nordisk Foundation
Responsible party
Sponsor
First posted
Apr 28, 2023
Start date
Jun 26, 2023
Primary completion
Jun 1, 2027 (estimated)
Completion
Jun 1, 2027 (estimated)
Last update
Nov 13, 2026

Study contacts

Sebastian Nielsen, MD
Contact
sebane@rm.dk
+45 23100484
Mark Reinhard, MD, PhD
Contact
markrein@rm.dk
+45 40460321
Mark Reinhard, MD, PhD
principal investigator · Aarhus University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion